Terazosin in benign prostatic hyperplasia: effects on blood pressure in normotensive and hypertensive men
- 1 September 1998
- journal article
- clinical trial
- Published by Wiley in British Journal of Urology
- Vol. 82 (3), 373-379
- https://doi.org/10.1046/j.1464-410x.1998.00747.x
Abstract
Objective To determine the effects of terazosin on blood pressure and on antihypertensive therapy when used in managing benign prostatic hyperplasia (BPH). Patients and methods Safety data from a large, multinational study were analysed retrospectively. Normotensive and hypertensive patients received escalating dosages of terazosin for 10 weeks and were maintained on 5 or 10 mg daily doses for 16 weeks (single‐blind period). After the initial treatment period, only men having sufficient improvements in International Prostate Symptom Score (≥30%) and in peak flow rate (≥10%) were randomly assigned to continue terazosin or to receive placebo for 24 weeks (double‐blind period). Results In hypertensive patients, terazosin reduced systolic blood pressure (SBP) and diastolic blood pressure (DBP) during the single‐blind period; these clinically significant reductions were maintained in patients receiving terazosin during the double‐blind period. However, in normotensive and controlled hypertensive patients terazosin produced no clinically significant mean changes in SBP or DBP during either study period. Terazosin did not adversely affect patients receiving concomitant antihypertensive medication. Conclusion Terazosin is a safe treatment for BPH in normotensive and hypertensive men, including men who are already taking additional antihypertensive drugs.Keywords
This publication has 32 references indexed in Scilit:
- A dose‐ranging study of the efficacy and safety of tamsulosin, the first prostate‐selective &agr;1A‐adrenoceptor antagonist*, in patients with benign prostatic obstructionBritish Journal of Urology, 1997
- Effects of alfuzosin on urethral and blood pressures in conscious male ratsLife Sciences, 1995
- Tamsulosin, a selective α1c‐adrenoceptor* antagonist: a randomized, controlled trial in patients with benign prostatic ‘obstruction’ (symptomatic BPH)British Journal of Urology, 1995
- New diagnostic and treatment guidelines for benign prostatic hyperplasia. Potential impact in the United StatesArchives of Internal Medicine, 1995
- Alpha1‐adrenoceptor subtypes in the human prostateBritish Journal of Urology, 1994
- Terazosin in the treatment of benign prostatic hyperplasia. Terazosin Benign Prostatic Hyperplasia Study GroupArchives of Family Medicine, 1993
- The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V)Archives of Internal Medicine, 1993
- The efficacy and safety of terazosin for the treatment of symptomatic BPHThe Prostate, 1991
- Efficacy of once-A-day terazosin in benign prostatic hyperplasia: A randomized, double-blind placebo-controlled clinical trialThe Prostate, 1990
- Concomitant administration of terazosin and atenolol for the treatment of essential hypertensionArchives of Internal Medicine, 1988